Interventional studies

Interventional studies are clinical research trials where researchers actively test a new drug, medical device, surgical procedure, or therapeutic approach on patients. Please contact us to express interest in any of these studies.

PRADA trial (Prescribing the Right Agent for Depression in Adults)

Due to open in Autumn 2026

The study team is looking for GP surgeries who would be interested in recruiting to the PRADA trial. The PRADA trial builds on the work of the PETRUSHKA trial.

PRADA advances the clinical decision support tool developed in PETRUSHKA by incorporating patients’ genetic profile to further personalise antidepressant treatment. In this new trial, the study team will compare the enhanced genetic-incorporated approach with their original precision tool, which tailors treatment based on demographics, depression history and side effect preferences.

TIMES definitive trial

Recruitment closes September 2026

Sleep disturbances are common among people living with dementia and mild cognitive impairment, but are often not self-reported, leading to impaired quality of life and breakdown of care. TIMES is a decision-support tool that aims to help GPs deliver tailored care plans that improve sleep and quality of life among these groups.

The team is looking for GP practices to recruit people living with dementia and mild cognitive impairment and their carers (family or professional) in pairs.

GP practices will be cluster randomised to deliver either the TIMES intervention or usual care.

Requirements:

• study set-up

• site initiation visit 

• participant identification 

• eligibility checks and screening 

• consent

• baseline visits (60 minutes per pair)

• follow-up visits at 9 and 15 weeks (60 minutes per dyad per visit)

• safety reporting

• study close-out

Intervention practices will also be requested to complete the following:

• GP intervention training (1-hour pre-recorded video, delivered in three ~15-minute sessions) 

• participant to complete brief onboarding questionnaire (SADL) 

• 1 30-minute in-person GP consultation per pair to develop a tailored care-plan 

• 1 15-minute in-person GP consultation per pair to review care-plan

• optional GP and/or admin time to participate in interviews, focus groups, surveys and questionnaires

Recruitment target per site: 7 patient-carer pairs per practice; 1-2 pairs per month, over a 4-month recruitment window

ESCAPE trial (Exacerbation and Symptom Control After Pseudomonas Eradication Treatment in Adult Bronchiectasis)

Recruitment closes May 2028

Bronchiectasis is the third most common lung condition in the UK; it causes people to suffer from cough and chest infections. 1 in 3 Bronchiectasis patients develop a further bacterial infection called Pseudomonas, which is difficult to treat as it often becomes resistant to antibiotic tablets. 

The Pseudomonas infection worsens the symptoms of Bronchiectasis. The aim of ESCAPE is to establish research backed basis for the best treatment path for new Pseudomonas infections by comparing two currently recommended treatments.

Requirements: Complete search, screen and manual mailout, 6 visits with each participant. The study team must be able to prescribe a nebulised antipseudomonal antibiotic and provide a nebuliser. Either Colistin, Gentamicin or Torbamycin.

Payments:

Service Support Costs

• one-off costs: preparation and database search - £69.63, check list for exclusions (per 30 patients) - £54

• Per participant costs:

First visit screening - £11.61

Informed consent by GP - £45

Informed consent by Nurse - £11.61

SAE Recording (if any) - £22.50

Research Costs

• One off costs: £828 site fee, £367 Archiving fee

• Per participant cost: £717.20 per patient randomised fee, £200 Participant travel expenses for in person visits (maximum amount per participant, to be reimbursed on actual cost)

AfLOAT trial (Antibiotics For LRTI in Older AdulTs)

Recruitment close: 01/05/2027

The AFLOAT trial will test whether placebo is non-inferior to antibiotics by assessing the duration of symptoms in patients presenting to primary with a  lower respiratory tract infection. 

Requirements:

Practice staff will be required to recruit eligible patients when they present during a routine appointment. This will require completion of :

• Eligibility assessment 

• Consent 

• Medical review (as per standard care) 

• Completion of baseline forms including symptom severity rating, Health related Quality of Life questionnaire 

• Randomisation and dispensing of IMP

Baseline activities can be done after the routine appointment by a delegated member of practice staff, however this will need to be done on the same day. A 28-day follow up medical notes review will also be required (approx. 15 minutes).

Payments:

Research costs if practice does NOT store theInvestigational Medicinal Product (IMP) on-site:

• site initiation visit: £352

• eCRF completion/data transfer/query resolution £68.25

• medical notes review £11.75

Research costs if practice DOES store the IMP onsite:

Receive the above research costs pus an extra:

• IMP temperature monitoring: 11.75 one-off fee

• Dispensing of IMP: £7.83 per patient

Service Support Costs - opportunistic recruitment, identifying patients who present to the practice: 

• £121.50 (one off fee)

• informed consent: £51 per patient

• eligibility assessment: £17 per patient

Excess Treatment Costs: £8.50 per patient